Role of traditional nonsteroidal anti-inflammatory drugs in Alzheimer's disease: A meta-analysis of randomized clinical trials

American Journal of Alzheimer's Disease and other Dementias

Volumn 30, Issue 2, 2015, Pages 178-182

  Gupta, Prem Prakash ^a   Pandey, Rishabh Dev ^b   Jha, Diwakar ^c   Shrivastav, Vikesh ^d   Kumar, Sandeep ^c  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b UTTARAKHAND TECHNICAL UNIVERSITY   (India)

^c BIT Meshra   (India)

^d SIRO Clinpharm DIL Premises   (India)

Author keywords

ADAS cog; Alzheimer's disease; MMSE

Indexed keywords

DICLOFENAC PLUS MISOPROSTOL; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO;

AD ASSESSMENT SCALE COGNITIVE SUBSCALE; ALZHEIMER DISEASE; ARTICLE; COCHRANE LIBRARY; DEMENTIA ASSESSMENT; EMBASE; HUMAN; INFORMATION RETRIEVAL; MEDLINE; META ANALYSIS; MINI MENTAL STATE EXAMINATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA;

ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84925666216     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317514542644     Document Type: Article

References (26)

1. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer's disease in the United States (2010-2050) estimated using the 2010 Census. Neurology. 2013 ; 80 (19). 1778-1783
2. Tsartsalis S, Panagopoulos PK, Mironidou-Tzouveleki M. Non-cholinergic pharmacotherapy approaches to Alzheimer's disease: the use of non-steroidal anti-inflammatory drugs. CNS Neurol Disord Drug Targets. 2011 ; 10 (1). 133-139
3. Doody RS. Cholinesterase inhibitors and memantine: best practices. CNS Spectr. 2008 ; 13: 34-35
4. Hoozemans JJ, Veerhuis R, Rozemuller JM, Eikelenboom P. Soothing the inflamed brain: effect of non-steroidal anti-inflammatory drugs on Alzheimer's disease pathology. CNS Neurol Disord Drug Targets. 2011 ; 10 (1). 57-67
5. Holly MB, Donna MW. Are inflammatory profiles the key to personalized Alzheimer's treatment. Neurodegen Dis Manage. 2013 ; 3 (4). 343-351
6. Tony WC, Rogers J. Inflammation in Alzheimer disease - a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med. 2012 ; 2 (1). a006346
7. Laura G, Ennio O, Gary W. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. J Neurochem. 2004 ; 91 (3). 521-536
8. In't Veld B. A, Ruitenberg A, Hofman A, et al. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001 ; 345 (21). 1515-1521
9. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. Br Med J. 2003 ; 327 (7407). 128-132
10. Jaturapatporn D, Isaac MG, McCleery J, et al. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev. 2012 ; 15 (2). CD006378
11. De Jong D, Jansen R, Hoefnagels W, et al. No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. PLoS ONE. 2008 ; 3 (1). e1475
12. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ. 2003 ; 327 (7407). 128
13. Neyeloff JL, Fuchs SC, Moreira LB. Meta-analyses and Forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC Res Notes. 2012 ; 5: 52
14. General methods for Cochrane reviews: http://handbook.cochrane.org/chapter-9/9-5-2-identifying-and-measuring-heterogeneity.htm
15. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003 ; 289 (21). 2819-2826
16. Hüll M, Bauer J. Treatment with the non-steroidal anti-inflammatory drug piroxicam-B-cyclodextrin in Alzheimer's disease. Ninth Congress of the International Psychogeriatric. Association. 1999 ; 107 (2). 15-20
17. Pasqualetti P, Bonomini C, Dal Forno G, et al. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease. Aging Clin Exp Res. 2009 ; 21 (2). 102-110
18. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993 ; 43 (8). 1609-1611
19. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology. 1999 ; 53 (1). 197-201
20. Martin BK, Szekely C, et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008 ; 65 (7). 896-905
21. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 ; 12 (3). 189-198
22. Lehrer S. Nasal NSAIDs for Alzheimer's Disease [published online January 9, 2014]. Am J Alzheimers Dis Other Demen. 2014 ;:
23. Mavridis D, Salanti G. How to assess publication bias: funnel plot, trim-and-fill method and selection models. Evid Based Ment Health. 2014 ; 17 (1). 30
24. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007 ; 28 (2). 105-114
25. Cakała M, Strosznajder JB. [The role of cyclooxygenases in neurotoxicity of amyloid beta peptides in Alzheimer's disease]. Neurol Neurochir Pol. 2010 ; 44 (1). 65-79
26. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health. 2011 ; 14 (4). 417-428